Cartesian Therapeutics Announces New Employment Inducement Grants
Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company focusing on mRNA cell therapies for autoimmune diseases, has announced inducement awards for five new employees. On October 1, 2024, the company granted these employees options to purchase a total of 60,961 shares of common stock at an exercise price of $17.11 per share, which was the closing price on Nasdaq on the grant date.
The options were issued under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board of directors. They will vest 25% on October 1, 2025, followed by three equal annual installments, becoming fully vested on October 1, 2028. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Positive
- Cartesian Therapeutics is attracting new talent with stock options as incentives
- The company is expanding its workforce, potentially indicating growth or new projects
Negative
- Granting of stock options may lead to potential dilution for existing shareholders
News Market Reaction – RNAC
On the day this news was published, RNAC gained 7.45%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Melissa Forst
Argot Partners
cartesian@argotpartners.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
How many new employees received stock options from Cartesian Therapeutics (RNAC) on October 1, 2024?
What is the exercise price of the stock options granted by Cartesian Therapeutics (RNAC) on October 1, 2024?
When will the stock options granted by Cartesian Therapeutics (RNAC) on October 1, 2024, be fully vested?
How many shares of common stock are covered by the options granted by Cartesian Therapeutics (RNAC) on October 1, 2024?
